I can't remember who was interested in information of leukemia and human milk
but Agennix, a company that manufactures recombinant human lactoferrin has
data supportive of the use of recombinant human lactoferrin in treatment of
cancers and mentions in particular leukemia.  There are many patents that
mention the use of human milk components (usually recombinants but based on
what real human milk components can do) in the treatment of cancer.  I find
it interesting that I found this research mentioned in one patent called,
"Lactoferrin variants and uses thereof."

Broxmeyer, "Potential Therapeutic Usefulness of Lactoferrin in Leukemia" in
Nestle Research News 1984/1985--p.93 (1986).

Interesting that it's just now that the media seems to be finally mentioning
that human milk components are useful in treatment of cancers.  But Nestle
knew it in 1984...Valerie W. McClain, IBCLC


http://www.agenix.com/lactoferrin/applications.html

    Agennix is currently conducting or will soon be starting clinical trials
in the areas of:

        Oncology - Treatment of Cancer
According to the National Cancer Institute, men have a 43% chance and woman
have a 38% chance, of developing cancer in their lifetime. Agennix will soon
be starting enrollment in two Phase II clinical trials on the effect of oral
lactoferrin on a variety of solid tumors.There is substantial animal data to
support these trials. There have been at least 16 different studies in mice
and rats in which lactoferrin demonstrated a significant anti-cancer effect.
These studies used a variety of routes of lactoferrin administration and
showed efficacy against a wide range of tumor types including some of the
most common types, such as lung and colorectal. A number of the studies had p
values less than 0.001, indicating there's less than one chance in a thousand
that results of this magnitude or greater would have occurred randomly.
Lactoferrin has also been shown, in a recently published study, to be
anti-angiogenic.
Oncology - Treatment of Infections in Cancer Patients Undergoing Chemotherapy
Agennix also has a double-blind, placebo controlled, Phase II trial ongoing
now at 14 centers in the UK, Germany and Belgium, on reducing infections and
mucositis in cancer patients undergoing myelosuppressive regimens of
chemotherapy.Human lactoferrin has been shown to reduce infections in human
clinical trials in both healthy volunteers and immuno-compromised
chemotherapy patients. In a trial involving 65 medical students visiting
Mexico for the summer, the higher dose of human lactoferrin reduced the
number of enteric pathogenic e.Coli infections by 74% relative to placebo.In
another trial in acute myologenous leukemia patients undergoing chemotherapy,
a low dose of lactoferrin, 800 mg per day administered orally, was able to
substantially reduce the duration of first infection from an average of 7.7
days to an average of 3.4 days, as well as reduce the use of antibiotics and
the severity of infection as judged by fever.
Respiratory Disease
In the respiratory area, Agennix will soon begin enrollment in a Phase I/II
human clinical trial in asthma. This is supported by human lactoferrin's
demonstrated efficacy in several sheep models of asthma that have predicted
human clinical efficacy with a number of asthma drugs.Both oral and inhaled
lactoferrin reduced the peak late phase lung inflammatory response in sheep
by 75 to 80%. Lactoferrin also completely abolished airway hypersensitivity.
And Lactoferrin dramatically reduced lung accumulation of inflammatory cells
linked to asthma following allergen challenge.












             ***********************************************
The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(TM)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html